Science
Semaglutide kidney trial maps how Ozempic-class drugs may slow diabetic kidney damage
Nature Medicine’s REMODEL study links weekly 1 mg semaglutide to lower renal artery resistance, fibrosis stabilization and glomerular endothelial changes — without meeting its coprimary MRI oxygenation and perfusion goals.
Published: October 1, 2026 · 1 min read
A 52-week randomized trial published Oct. 1 in Nature Medicine offers the clearest human-tissue look yet at how the GLP-1 receptor agonist semaglutide may protect kidneys in people with type 2 diabetes and chronic kidney disease — even as its main MRI endpoints missed statistical significance. In the REMODEL trial (NCT04865770), 106 participants were randomized 2:1 to subcutaneous semaglutide 1 mg once weekly or placebo. Coprimary multiparametric MRI outcomes — kidney oxygenation (R2*), global perfusion and T1 inflammation mapping — were not significantly different between groups after a year. Secondary imaging, however, showed a lower renal artery resistive index and higher cortical apparent diffusion coefficient with semaglutide, findings the authors interpret as reduced vascular resistance and prevention of fibrosis progression. Exploratory clinical signals included a roughly 40% drop in urinary albumin-to-creatinine ratio versus placebo and higher 24-hour creatinine clearance; body weight and HbA1c also fell more with the drug, as expected. Paired kidney biopsies with single-nucleus RNA sequencing and spatial transcriptomics pointed to glomerular endothelial cells as the most treatment-responsive populations, with reduced nearby immune cells after semaglutide and gene-expression shifts tied to metabolic stress, inflammation and fibrosis pathways. Histology suggested a smaller fractional intimal area in the most diseased arterioles. The trial was funded by Novo Nordisk, maker of semaglutide products, and several authors are company employees or consultants; results should be read alongside the larger FLOW outcomes trial rather than as a new prescribing mandate. For Canadian clinicians already pairing GLP-1 drugs with SGLT2 inhibitors, REMODEL’s mechanistic map — lower kidney fat, improved microvascular signals, endothelial transcript changes — helps explain outcome benefits beyond weight loss, while underscoring that MRI coprimaries were negative and the biopsy subgroup was small. This article summarizes peer-reviewed research for general information only. It is not a substitute for professional medical advice, diagnosis or treatment. Consult a qualified clinician before changing any medication or care plan. Sources: Nature Medicine Effects of semaglutide on kidney disease in type 2 diabetes; ClinicalTrials.gov NCT04865770.
Newsletter
News. Context. What matters.
One essential briefing, written for people who would rather understand the story than scroll it.
Unsubscribe anytime. We don’t sell addresses.
Recommended
Science
From the space station, Joshua Kutryk describes the northern lights and relearning daily life as Canadian health studies get under way
In his first news conference from orbit, the Canadian Space Agency astronaut said he has lost five pounds and is taking part in Canadian-led research on astronaut health; a SpaceX cargo ship launched Tuesday with more experiments.
Science
About one in six Canadian doctors reports a disability at least some of the time, CMAJ census study finds
An Ottawa Hospital-led analysis of 2021 long-form census data found mental health and vision were the most commonly reported disabilities, and its authors call for more accessible medical workplaces.
Science
More than half of species assessed at risk since 2017 are overdue for federal listing decisions, SFU-led study finds
Only 17 of 288 COSEWIC-assessed species reached Cabinet on time; none of the marine mammals or marine fish assessed in the period had been forwarded by January 2025, researchers report in FACETS.